Inovio’s upside hinges on INO-3107 for HPV-6/11 RRP with FDA PDUFA Oct 2026, regulatory risk, tight cash, and cheap EV. Check ...

Inovio stock down as FDA accepts BLA for INO-3107, but notes insufficient info for accelerated approval pathway. Meeting ...

Inovio Pharmaceuticals (NASDAQ:INO) is preparing to release its quarterly earnings on Thursday, 2024-11-14. Here's a brief overview of what investors should keep in mind before the announcement.

This was the stock's third consecutive day of losses.

The stock price of Inovio Pharmaceuticals (NYSE: INO), a biotechnology company focused on synthetic DNA products for treating cancers and infectious diseases, has seen a large fall of 17% over the ...

Shares of Inovio Pharmaceuticals pulled back by 5.3% during Wednesday’s session. The decline may be attributed to profit-taking, as investors assess renewed focus on respiratory illnesses. See the ...